Impact of Sofosbuvir and Daclatasvir on Blood Vessel Formation in HCV Patients
Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection
This study tests whether the antiviral medications Sofosbuvir and Daclatasvir can affect the growth of new blood vessels in Egyptian patients with chronic Hepatitis C.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT03646396 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of the antiviral medications Sofosbuvir and Daclatasvir on angiogenesis in patients with chronic Hepatitis C virus (HCV) infection. It focuses on Egyptian patients to understand how these treatments may influence the formation of new blood vessels in the context of HCV coinfection. The study aims to provide insights into the potential mechanisms by which these antiviral agents may affect disease progression and related complications.
Who should consider this trial
Good fit: Ideal candidates for this study are Egyptian patients diagnosed with chronic HCV infection.
Not a fit: Patients with Hepatocellular carcinoma (HCC), HIV or HBV infections, malignancies, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with chronic HCV infection by understanding the role of angiogenesis.
How similar studies have performed: While there is limited data on the specific combination of Sofosbuvir and Daclatasvir affecting angiogenesis, similar antiviral treatments have shown promise in improving outcomes for HCV patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic HCV patients Exclusion Criteria: * HCC. * HIV or HBV. * Malignancy. * Pregnancy.
Where this trial is running
Tanta
- Sherief Abd-Elsalam — Tanta, Egypt (Recruiting)
Study contacts
- Principal investigator: Eman h abd El-Razek, Msc — Clinical pharmacy Department- Tanta University
- Study coordinator: Sherief Abd-Elsalam, MD
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.